ArticleCureus2025
Multiple Subcutaneous Metastases in Endometrial Cancer Treated With Systemic Chemotherapy: A Case Report and Review of the Literature.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Subcutaneous metastasis of endometrial cancer (EC) is an exceedingly rare phenomenon, and the mechanisms underlying its pathogenesis remain insufficiently elucidated. We report the case of a 69-year-old multiparous woman diagnosed with stage IB EC, histologically classified as grade 3 endometrioid and clear cell carcinoma. Approximately one month following primary surgical intervention, the patient developed subcutaneous masses on her back, axilla, and buttock. Histopathological evaluation, in conjunction with PET-CT, confirmed a systemic recurrence of EC. She was subsequently treated with a combination of paclitaxel and carboplatin, with a remarkable therapeutic response; after six cycles of chemotherapy, nearly all metastatic sites exhibited complete resolution. She was then transitioned to a regimen of lenvatinib and pembrolizumab. However, one week after the initiation of this treatment, she developed hepatic encephalopathy, which was presumed to be lenvatinib-induced, and was successfully managed with aminoleban injections, resulting in a full recovery of consciousness. Follow-up diagnostic imaging confirmed a complete response to therapy. The patient is currently receiving pembrolizumab as maintenance therapy and has remained recurrence-free for 18 months. While no standardized therapeutic protocol exists for the management of subcutaneous metastasis in EC due to its extremely low incidence, this report provides evidence for the potential efficacy of chemotherapy combined with targeted immunotherapy in the treatment of unresectable subcutaneous metastases in EC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.